Excerpt

To prohibit brand name drug manufacturers from compensating generic drug manufacturers to delay the entry of a generic drug into the market, to prohibit biological product manufacturers from compensating biosimilar and interchangeable product manufacturers to delay entry of biosimilar and interchangeable products, and for other purposes.

Verbatim excerpt from the bill text — not a summary. Taken from the “Introduced in House” version of the bill.

Bill text

Read the full text of the Introduced in House version (10/22/2026), exactly as published — 19,336 characters.

• Introduced in House10/22/2026On HeardOfficial document (HTML)

No roll-call votes recorded for this bill yet.